Key Takeaways
- • Charterhouse Capital Partners completed a £235.2 million take-private acquisition of Animalcare Group PLC, a York-headquartered veterinary pharmaceuticals company, taking the business off public markets.
- • The deal was announced on 15-16 April 2026 as a recommended offer and has now completed, with Charterhouse acquiring the company from existing shareholders including Harwood Capital LLP and Marc Coucke.
- • Charterhouse intends to partner with Animalcare's existing management team to support the next phase of growth, signaling continuity in operational leadership despite the change in ownership structure.
- • The transaction values the animal health business at £235.2 million, reflecting private equity appetite for veterinary pharmaceutical assets in the pet care sector.
Summary
Charterhouse Capital Partners LLP has completed its £235.2 million acquisition of Animalcare Group PLC, taking the UK-based veterinary pharmaceuticals company private. The York-headquartered business, which was previously listed on public markets, is now wholly owned by the private equity firm following completion of the transaction that was first announced in mid-April 2026.
The deal structure involved Charterhouse acquiring Animalcare's securities through a special purpose vehicle, CCP Paw 2 Limited, from existing shareholders Harwood Capital LLP, Marc Coucke, and others. The transaction was presented to shareholders as a recommended offer and received the necessary acceptances to proceed to completion.
Charterhouse has signaled its commitment to supporting Animalcare's growth trajectory by retaining the incumbent management team. The firm positioned itself as a long-term partner capable of deploying capital and identifying investment opportunities within the animal health market, emphasizing operational continuity rather than a restructuring approach typical of some private equity transitions. This strategy aligns with Charterhouse's stated objective of supporting the veterinary pharmaceuticals business through its next growth phase while leveraging the existing management's expertise and market knowledge in the pet care sector.
The completion of this take-private transaction removes Animalcare from public equity markets and reflects ongoing private equity interest in specialized healthcare and pharmaceutical subsectors, particularly those serving the growing pet care industry.
The deal structure involved Charterhouse acquiring Animalcare's securities through a special purpose vehicle, CCP Paw 2 Limited, from existing shareholders Harwood Capital LLP, Marc Coucke, and others. The transaction was presented to shareholders as a recommended offer and received the necessary acceptances to proceed to completion.
Charterhouse has signaled its commitment to supporting Animalcare's growth trajectory by retaining the incumbent management team. The firm positioned itself as a long-term partner capable of deploying capital and identifying investment opportunities within the animal health market, emphasizing operational continuity rather than a restructuring approach typical of some private equity transitions. This strategy aligns with Charterhouse's stated objective of supporting the veterinary pharmaceuticals business through its next growth phase while leveraging the existing management's expertise and market knowledge in the pet care sector.
The completion of this take-private transaction removes Animalcare from public equity markets and reflects ongoing private equity interest in specialized healthcare and pharmaceutical subsectors, particularly those serving the growing pet care industry.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.